Amgen Inc. $AMGN Shares Sold by Diversified Trust Co.

Diversified Trust Co. lessened its stake in Amgen Inc. (NASDAQ:AMGN) by 5.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 40,349 shares of the medical research company’s stock after selling 2,332 shares during the quarter. Diversified Trust Co.’s holdings in Amgen were worth $13,207,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. West Family Investments Inc. raised its holdings in Amgen by 1.1% in the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after acquiring an additional 30 shares in the last quarter. Viawealth LLC lifted its stake in Amgen by 0.4% in the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock worth $2,023,000 after acquiring an additional 30 shares during the last quarter. LOM Asset Management Ltd grew its holdings in Amgen by 1.2% during the 3rd quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock worth $721,000 after acquiring an additional 30 shares in the last quarter. Sittner & Nelson LLC increased its position in shares of Amgen by 0.4% in the 3rd quarter. Sittner & Nelson LLC now owns 7,276 shares of the medical research company’s stock valued at $2,053,000 after purchasing an additional 30 shares during the last quarter. Finally, TAGStone Capital Inc. increased its position in shares of Amgen by 0.8% in the 3rd quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock valued at $1,157,000 after purchasing an additional 32 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently issued reports on AMGN. Royal Bank Of Canada lifted their price objective on shares of Amgen from $335.00 to $360.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 4th. Argus lifted their price target on Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Erste Group Bank raised Amgen from a “hold” rating to a “buy” rating in a research report on Friday, December 5th. Piper Sandler boosted their target price on Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Finally, Truist Financial increased their price target on shares of Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $354.60.

Amgen Stock Performance

NASDAQ AMGN opened at $349.77 on Tuesday. The company has a fifty day moving average of $360.77 and a two-hundred day moving average of $328.60. The company has a market capitalization of $188.55 billion, a PE ratio of 24.58, a P/E/G ratio of 3.45 and a beta of 0.45. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter in the previous year, the firm earned $5.31 earnings per share. The business’s revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.9%. Amgen’s payout ratio is 70.84%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.